Finally, the future success of autologous transplantation of genetically repaired or in vitro expanded organoids in patients, abolishing the need
for allogeneic donors and for lifelong immunosuppression, is dependent on a significant improvement in engraftment efficiency.
Initially, and during the first 10 - 15 years of cord blood transplantation, cord blood was predominantly used as a source
of allogeneic donor cells.
Compared with the toxicity that we see
with allogeneic donor hematopoietic stem cell therapy, these toxicities are relatively manageable with close monitoring and close supportive care.